This receptor, present exclusively on myeloid cells, represents the predominant activating FcγR present on neutrophils, and it has been demonstrated to be the principal mediator of neutrophil ADCC through recognition of the IgG tail of cancer-targeting therapeutic antibodies directed against other solid cancer cells [18,19,20]. This evidence concerns the gene FCGR2A and cancer.